A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer
Overview
Authors
Affiliations
Cytotoxic T-lymphocyte-antigen 4 (CTLA-4) is an essential negative regulator expressed on regulatory T cells (Tregs) and activated T cells. Germline heterozygous mutations in CTLA4 lead to haploinsufficiency of CTLA-4, resulting in the development of an autosomal dominant immune dysregulation syndrome with incomplete penetrance. We report here a Japanese patient with this disorder who has a novel heterozygous single nucleotide insertion, 76_77insT (p. L28SfsX40), in the CTLA4 gene. Peripheral blood mononuclear cells from the patient showed decreased frequency of CTLA-4(high) cells in CD4(+)FOXP3(+) cells following CD3/CD28 stimulation. The patient experienced hypogammaglobulinemia, recurrent pneumonia, esophageal candidiasis, cytomegalovirus-positive chronic gastritis, chronic and severe diarrhea, and type 1 diabetes mellitus. Moreover, the patient developed multifocal gastric cancer, histologically poorly and well-differentiated adenocarcinomas, associated with chronic atrophic gastritis and intestinal metaplasia. Previously, 23 symptomatic cases with heterozygous CTLA4 mutations have been reported. Including the case presented here, 3 of the 24 cases (12.5%) developed gastric cancer. Notably, 2 of 3 patients presented similarly multifocal adenocarcinomas associated with atrophic gastritis and intestinal metaplasia. Predisposition to gastric cancer has been also reported in CVID patients. These clinical observations suggest that gastric cancer is a disease commonly associated with autosomal dominant immune dysregulation syndrome due to CTLA4 mutation.
Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis.
Fekrvand S, Abolhassani H, Esfahani Z, Fard N, Amiri M, Salehi H J Clin Immunol. 2024; 45(1):34.
PMID: 39466473 DOI: 10.1007/s10875-024-01810-w.
Diaz-Alberola I, Espuch-Oliver A, Fernandez-Segovia F, Lopez-Nevot M Microorganisms. 2024; 12(6).
PMID: 38930460 PMC: 11205354. DOI: 10.3390/microorganisms12061078.
Meraviglia-Crivelli D, Villanueva H, Zheleva A, Villalba-Esparza M, Moreno B, Menon A Mol Cancer. 2022; 21(1):211.
PMID: 36443756 PMC: 9703761. DOI: 10.1186/s12943-022-01679-6.
Genetics of Immune Dysregulation and Cancer Predisposition: Two Sides of the Same Coin.
Matza Porges S, Shamriz O Clin Exp Immunol. 2022; 210(2):114-127.
PMID: 36165533 PMC: 9750831. DOI: 10.1093/cei/uxac089.
Zheng B, Artin M, Chung H, Chen B, Sun S, May B J Gastroenterol Hepatol. 2022; 37(6):973-982.
PMID: 35384041 PMC: 9301767. DOI: 10.1111/jgh.15848.